Annexin 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANXV / Annexin
2021-002200-12: The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19. De CO-ANNEXIN studie; onderzoek naar de effectiviteit en veiligheid van ANXV (recombinant Annexine A5) inmatig tot ernstige COVID-19.

Ongoing
2
12
Europe
AnnexinV, Injection
MUMC AZm, Annexinpharmaceuticals
moderate to severe COVID-19 pneumonia patiënten met matig tot ernstige COVID-19 oneumonie, patients with moderate to severe covid-19 pneumoniae patiënten met matig tot ernstige COVID-19 pneumonie, Diseases [C] - Immune System Diseases [C20]
 
 
NCT05532735: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

Active, not recruiting
2
16
US
ANXV
Annexin Pharmaceuticals AB, InFocus Clinical Research
Retinal Vein Occlusion
07/24
11/24

Download Options